## Diagnostics for STH: MDA decisions and TPP





BILL&MELINDA

GATES foundation

## Graham Medley, LSHTM

Hugo Turner, Imperial College Rebecca Baggaley, LSHTM Celia Holland, TCD, Eire Dèirdre Hollingsworth, Warwick Rachel Pullan, LSHTM

**Medley, G.F**., Turner, H.C., Baggaley, R.F., Holland, C., Hollingsworth, T.D. (2016). The Role of More Sensitive Helminth Diagnostics in Mass Drug Administration Campaigns: Elimination and Health Impacts. *Advances in Parasitology*, Volume **94**, pp. 343–392. <u>http://dx.doi.org/10.1016/bs.apar.2016.08.005</u>





Increasing sensitivity of diagnostic results in better control where possible – more chemotherapy in midprevalence communities

## **Diagnostics Influence MDA Decisions**

- The impact of improved (more sensitive) diagnostics for STH depends on their use for decision-making
  - Guidelines (e.g. 30% threshold) are based on APPARENT prevalence
  - Create a barrier to improved diagnostics what is 30% by KK in terms of a different diagnostic?
- <u>APPARENT</u> prevalence is different from <u>TRUE</u> prevalence
  - Discrepancy changes with true prevalence
  - True prevalence is never known

## **Target Product Profiles**

- Diagnostic influences
  - Individual-level sensitivity and specificity
  - Pooling of samples
- Epidemiological influences
  - Sources of heterogeneity sampling frames
  - Systematic non-compliance
  - Spatial & population effects
- Economics
  - Cost (value) of prevalence estimates vs. Human and financial costs of incorrect decisions
    - Epidemiology
      - Transport, labour, sample size
    - Diagnostic
      - Type of sample; Laboratory requirements
- For a given diagnostic, how would it best be used and what is the impact on MDA decisions to stop and re-start



<u>APPARENT</u> prevalence is different from <u>TRUE</u> prevalence, and the discrepancy changes with true prevalence True prevalence is never known